Evaxion A/S American
EVAX
Evaxion A/S American Depositary Share represents ownership in Evaxion A/S, a Denmark-based clinical-stage biotechnology company focused on AI-immunology powered vaccines. The company develops artificial intelligence-driven solutions for discovering and designing vaccines and immunotherapies aimed at cancer and infectious diseases. Its current work centers on using proprietary platforms to analyze immune-system data and support the creation of vaccine candidates for oncology, bacterial disease, and viral disease applications. Evaxion operates as a techbio company at the intersection of biotechnology and artificial intelligence, combining computational methods with immunology research to advance drug discovery. Through its American Depositary Shares, investors gain access to a company whose business is built around vaccine development and immune-based therapeutic research in the global healthcare market.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$7M
▲ +125.1% YoY
Net Income (TTM)
-$9M
▲ +27.1% YoY
Op. Margin
-116.04%
▲ +317.9pp YoY
ROIC
-42.11%
▲ +68.9pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$7M
▲ +48.7% YoY
Op. Cash Flow (FY)
-$7M
▲ +26.0% YoY
Net Debt
-$16M
Net Cash Position
Cash & Equiv.
$23M
Continue Research
Peers
Biotechnology · Pick stocks to compare with EVAX
Evaxion A/S American (EVAX) in four numbers
Questions about Evaxion A/S American
Is Evaxion A/S American (EVAX) overvalued?
At $2.26, Evaxion A/S American's price is 70% below the $7.41 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Evaxion A/S American's fair value?
Intrinsiqq's calculator puts Evaxion A/S American's fair value at $7.41 a share. It grows revenue per share 30% a year for 5 years, applies an exit P/S of 3.2, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $5.56. Every input can be changed on the Intrinsic Value tab.
Is Evaxion A/S American a high-quality business?
Evaxion A/S American scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$16M, and its weakest is return on capital at -42.1%. The Quality tab shows every check against its target.
Does Evaxion A/S American (EVAX) pay a dividend?
No. Evaxion A/S American (EVAX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing EVAX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.